YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지
DOI QR코드

DOI QR Code

An Analysis of Prescription Patterns and Incidence of Dyslipidemia in a Korean Tertiary Hospital HIV Patients Receiving High Active Antiretroviral Therapy

3차 병원에서 HAART 치료를 받은 HIV 환자의 처방패턴 및 이상지질혈증 발생 빈도 분석

  • Received : 2015.02.09
  • Accepted : 2015.05.31
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Highly active antiretroviral therapy (HAART) has reduced AIDS-related morbidity and mortality; however, it has been associated with metabolic abnormalities including dyslipidemia and dysglycemia depending on the regimens used. The aims of this study were to analyze the prescription patterns of antiretroviral agents and to examine the prevalence of lipid abnormalities among the prescriptions of HAART. The electronic medical records (EMR) of HIV patients were retrospectively reviewed from January 2007 to September 2012 based on our inclusion criteria. The patients who had taken HAART for at least 3 months were included in this study. The lipid profiles of patients on antiretrovirals (ARTs) were collected from his or her laboratory data, and dyslipidemia was defined as total cholesterol (TC) ${\geq}240mg/dL$ and triglycerides (TG) >200 mg/dL. Eighty-four prescriptions were discovered during the study period. Twenty-three prescriptions were the combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). Fifty-three prescriptions were the combination of two NRTIs and one protease inhibitor (PI) and thirty-nine prescriptions of them included a PI booster. Eight prescriptions were the combination of two NRTIs and one integrase inhibitor. The Incidence of hypertriglyceridemia among the patients receiving HAART was totally about 41.7% (2NRTIs+PI regimen vs. 2NRTIs+NNRTI regimen vs. 2 NRTIs+integrase inhibitor regimen, 52% vs. 12.5% vs. 25%), but there was no incidence of hypercholesterolemia. This study investigated that the prescription medication patterns and dyslipidemia associated with lipid abnormalities among HIV patients receiving HAART. The types of HAART prescription regimens had an effect on the occurrence of hypertriglycemia. Further studies related to metabolic abnormalities and adverse effects of HIV patients on ARTs are needed in the near future.

Keywords

References

  1. Lo, J. : Dyslipidemia and lipid management in HIV-infected patients. Curr. Opin. Endocrinol. Diabetes Obes. 18, 144 (2011). https://doi.org/10.1097/MED.0b013e328344556e
  2. Sprinz, E., Lazzaretti, R. K., Kuhmmer, R. and Ribeiro, J. P. : Dyslipidemia in HIV-infected individuals. Braz. J. Infect. Dis. 14, 575 (2010). https://doi.org/10.1016/S1413-8670(10)70115-X
  3. Estrada, V. and Portilla, J. : Dyslipidemia related to antiretroviral therapy. AIDS Rev. 13, 49 (2011).
  4. Grinspoon, S. and Carr, A. : Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352, 48 (2005). https://doi.org/10.1056/NEJMra041811
  5. Imamura, A. : Antiretroviral therapy of HIV infection. Nihon. Rinsho. 70, 601 (2012).
  6. Stanley, T. L. and Grinspoon, S. K. : Body composition and metabolic changes in HIV-infected patients. J. Infect. Dis. 205 Suppl 3, S383 (2012). https://doi.org/10.1093/infdis/jis205
  7. Fichtenbaum, C. J. : Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons. HIV Clin. Trials 5, 416 (2004). https://doi.org/10.1310/P07M-HNT8-L08G-5TKU
  8. Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., d'Arminio Monforte, A., Pradier, C., Morfeldt, L., Mateu, S., Law, M., El-Sadr, W., De Wit, S., Sabin, C. A., Phillips, A. N. and Lundgren, J. D. : Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179 (2003).
  9. Villarroya, F., Domingo, P. and Giralt, M. : Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim. Biophys. Acta 1801, 392 (2010). https://doi.org/10.1016/j.bbalip.2009.09.018
  10. Croxtall, J. D. and Perry, C. M. : Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs 70, 1885 (2010). https://doi.org/10.2165/11204950-000000000-00000
  11. Podzamczer, D., Andrade-Villanueva, J. Clotet, B., Taylor, S., Rockstroh, J. K., Reiss, P., Domingo, P., Gellermann, H. J., de Rossi, L., Cairns, V. and Soriano, V. : Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Med. 12, 374 (2011). https://doi.org/10.1111/j.1468-1293.2011.00917.x
  12. Lu, C. L., Lin, Y. H., Wong, W. W., Lin, H. H., Ho, M. W., Wang, N. C., Hsieh, S. M., Sheng, W. H., Hung, C. C. and Chen, M. Y. : Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. J. Microbiol. Immunol. Infect. 44, 258 (2011). https://doi.org/10.1016/j.jmii.2010.08.003
  13. Kramer, A. S., Lazzarotto, A. R., Sprinz, E. and Manfroi, W. C. : Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV. Arq. Bras. Cardiol. 93, 561 (2009). https://doi.org/10.1590/S0066-782X2009001100019
  14. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents (2012). Available at: http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl003093.pdf (Accessed on February 5, 2015).
  15. Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer, H. B. Jr., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C. Jr. and Stone, N. J. : Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110, 227 (2004). https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  16. Giuntini, R., Martinelli, C., Ricci, E., Vichi, F., Gianelli, E., Madeddu, G., Abeli, C., Palvarini, L., Penco, G., Marconi, P., Grosso, C., Pellicano, G., Bonfanti, P. and Quirino, T. : Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med. 11, 40 (2010). https://doi.org/10.1111/j.1468-1293.2009.00740.x
  17. Vrouenraets, S. M., Wit, F. W., Fernandez Garcia, E., Moyle, G. J., Jackson, A. G., Allavena, C., Raffi, F., Jayaweera, D. T., Mauss, S., Katlama, C., Fisher, M., Slama, L., Hardy, W. D., Dejesus, E., van Eeden, A. and Reiss, P. : Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1-infected patients. HIV Med. 12, 620 (2011). https://doi.org/10.1111/j.1468-1293.2011.00941.x
  18. Bonnet, F., Aurillac-Lavignolle, V., Breilh, D., Thiébaut, R., Peuchant, E., Bernard, N., Lacoste, D., Dabis, F., Beylot, J., Chêne, G. and Morlat, P. : Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin. Trials 8, 53 (2007). https://doi.org/10.1310/hct0801-53
  19. Singh, S., Willig, J. H., Mugavero, M. J., Crane, P. K., Harrington, R. D., Knopp, R. H., Kosel, B. W., Saag, M. S., Kitahata, M. M. and Crane, H. M. : Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin. Infect. Dis. 52, 387 (2011). https://doi.org/10.1093/cid/ciq111
  20. Aslangul, E., Assoumou, L., Bittar, R., Valantin, M. A., Kalmykova, O., Peytavin, G., Fiévet, M. H., Boccara, F., Bonnefont-Rousselot, D., Melchior, J. C., Giral, P. and Costagliola, D. : Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients received protease inhibitors: a randomized trial. AIDS 24, 77 (2010). https://doi.org/10.1097/QAD.0b013e328331d2ab
  21. Korea Center for Disease Control and Prevention. Annual report on the notified HIV/AIDS in Korea. Available at: www.cdc.go.kr (accessed on February 4, 2015).
  22. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2009). Available at: http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl001419.pdf (accessed on February 3, 2015).
  23. Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., Stancil, B., Mosteller, M., Brothers, C., Wannamaker, P., Hughes, A., Sutherland-Phillips, D., Mallal, S. and Shaefer, M. : High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111 (2008). https://doi.org/10.1086/529382
  24. Park, W. B., Choe, P. G., Song, K. H., Lee, S., Jang, H. C., Jeon, J. H., Park, S. W., Park, M. H., Oh, M. D. and Choe, K. W. : Should HLA*5701 screening be performed in every ethnic group before starting abacavir?. Clin. Infect. Dis. 48, 365 (2009). https://doi.org/10.1086/595890
  25. Duong Van Huyen, J. P., Batisse, D., Bélair, M. F. and Bruneval, P. : Mitochondrial hepatic toxicity associated with antiretroviral treatment. Ann. Pathol. 25, 299 (2005). https://doi.org/10.1016/S0242-6498(05)80134-8
  26. Surgers, L. and Lacombe, K. : Hepatoxicity of new antiretrovirals: a systematic review. Clin. Res. Hepatol. Gastroenterol. 37, 126 (2013). https://doi.org/10.1016/j.clinre.2013.02.008
  27. Lennox, J. L., Dejesus, E., Berger, D. S., Lazzarin, A., Pollard, R. B., Ramalho Madruga, J. V., Zhao, J., Wan, H., Gilbert, C. L., Teppler, H., Rodgers, A. J., Barnard, R. J., Miller, M. D., Dinubile, M. J., Nguyen, B. Y., Leavitt, R. and Sklar, P. : Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune. Defic. Syndr. 55, 39 (2010). https://doi.org/10.1097/QAI.0b013e3181da1287
  28. Buchacz, K., Baker, R. K., Palella, F. J., Shaw, L., Patel, P., Lichtenstein, K. A., Chmiel, J. S., Vellozzi, C., Debes, R., Henry, K., Overton, E. T., Bush, T. J., Tedaldi, E., Carpenter, C., Mayer, K. H. and Brooks, J. H. : Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir. Ther. 18, 65 (2013).
  29. Orkin, C., DeJesus, E., Khanlou, H., Stoehr, A., Supparatpinyo, K., Lathouwers, E., Lefebvre, E., Opsomer, M., van de Casteele, T. and Tomaka, F. : Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 14, 49 (2013).
  30. Korean Society for AIDS : The 2013 clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect. Chemother. 45, 455 (2013). https://doi.org/10.3947/ic.2013.45.4.455
  31. Korean Society for AIDS : Clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect. Chemother. 43, 89 (2011). https://doi.org/10.3947/ic.2011.43.2.89